The Preclinical Therapeutics Core (Core) provides in vivo services to UCSF Helen Diller Family Comprehensive Cancer Center (Center) investigators. Offering a variety of tumor engraftment-based cancer models for use in preclinical oncology trials, the Core provides a complete set of services that include consultation regarding experimental design, tumor cell culture and implantation in mice, administration of experimental agents, monitoring of tumor burden and response to therapy, and interpretation of study results. The Core maintains a cryorepository of commonly used human cancer cell lines derived from multiple tumor types along with data regarding their in vivo growth characteristics, as well as a collection of patient-derived tumor xenograft models. The Core's offerings also include pharmacological analysis and optimization of novel agents such as compound formulation, pharmacokinetics (PK), pharmacodynamics (PD), and safety-toxicity analyses. The Core is also a resource of expertise in small animal survival surgery, and is available to provide training in these techniques on a recharge basis. Although the Core primarily functions to test experimental anti-cancer agents in vivo, it also provides animal models of human cancer for use in novel diagnostic, tumor imaging, and basic mechanistic research. The Core oversees, maintains, and provides as a service a number of small animal imaging technologies housed within the barrier facility. The availability of centralized cell and animal resources, together with personnel with expertise in conducting preclinical studies, ensures appropriate experimental design and reproducibility, compliance with local and federal regulatory guidelines for tumor-bearing animals, and maximum resource utilization through coordinated animal purchasing and housing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-16
Application #
8693947
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
16
Fiscal Year
2014
Total Cost
$263,196
Indirect Cost
$96,533
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications